A selective CysLT1 receptor antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Zafirlukast

Item No. 10008282

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
[3-[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]-carbamic acid, cyclopentyl ester
CAS Number
107753-78-6
Molecular Formula
C31H33N3O6S
Formula Weight
575.7
Purity
≥97%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMF:PBS (pH 7.2) (1:1): .5 mg/mlDMSO: 20 mg/mlEthanol: .25 mg/ml
λmax
203, 215, 241, 299 nm
SMILES
COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C
InChi Code
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
InChi Key
YEEZWCHGZNKEEK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 mg

    $28

    Add

    100 mg

    $125

    Add

    500 mg

    $482

    Add

    1 g

    $825

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Zafirlukast is a cysteinyl leukotriene 1 (CysLT1) receptor antagonist (IC50 = 0.014 μM in a cell-based calcium mobilization assay).1 It is selective for CysLT1 over CysLT2 receptors (IC50 = 58 μM). It inhibits mucus secretion induced by leukotriene D4 (LTD4; Item No. 20310) in isolated guinea pig trachea (IC50 = 0.6 μM).2 Zafirlukast (5 μM) inhibits ovalbumin-induced increases in tracheal mucus secretion in ovalbumin-sensitized guinea pigs by 65%. It inhibits LTD4-induced bronchoconstriction in anesthetized guinea pigs (ED50 = 61 nmol/kg, i.v.).3 Formulations containing zafirlukast have been used in the prophylaxis and chronic treatment of asthma.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chen, H., Yang, H., Wang, Z., et al. Discovery of 3-substituted 1H-indole-2-carboxylic acid derivatives as a novel class of CysLT1 selective antagonists. ACS Med. Chem. Lett. 7(3), 335-339 (2016).

    2. Liu, Y.-C., Khawaja, A.M., and Rogers, D.F. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br. J. Pharmacol. 124(3), 563-571 (1998).

    3. Cabré, F., Carabaza, A., García, A.M., et al. Pharmacological profile of MEN91507, a new CysLT1 receptor antagonist. Eur. J. Pharmacol. 451(3), 317-326 (2002).

    Product Citations

    Nagai, J., Balestrieri, B., Fanning, L.B., et al. P2Y6 signaling in alveolar macrophages prevents leukotriene-dependent type 2 allergic lung inflammation. J. Clin. Invest. 129(12), 5169-5186 (2019).